Emerging Benefits: Pathophysiological Functions and Target Drugs of the Sigma-1 Receptor in Neurodegenerative Diseases

被引：34

作者：

Wu, Ning-hua ^{[1
,2
]}

Ye, Yu ^{[1
]}

Wan, Bin-bin ^{[1
]}

Yu, Yuan-dong ^{[3
]}

Liu, Chao ^{[1
]}

Chen, Qing-jie ^{[1
]}

机构：

[1] Hubei Univ Sci & Technol, Hubei Key Lab Diabet & Angiopathy, Xianning 437000, Hubei, Peoples R China

[2] Hubei Univ Sci & Technol, Basic Med Coll, Xianning 437000, Hubei, Peoples R China

[3] Hubei Univ Med, Renmin Hosp, Dept Oncol, Shiyan 442000, Hubei, Peoples R China

来源：

MOLECULAR NEUROBIOLOGY | 2021年 / 58卷 / 11期

基金：

中国国家自然科学基金;

关键词：

Sigma-1; receptor; MAM; Neurodegenerative; SIGMAR1; Target drugs; ENDOPLASMIC-RETICULUM; NEUROTROPHIC FACTOR; MOUSE MODEL; PAIN HYPERSENSITIVITY; NEUROPATHIC PAIN; BRAIN PLASTICITY; RAT MODEL; ACTIVATION; PATHWAY; DYSFUNCTION;

D O I：

10.1007/s12035-021-02524-5

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

The sigma-1 receptor (Sig-1R) is encoded by the SIGMAR1 gene and is a nonopioid transmembrane receptor located in the mitochondrial-associated endoplasmic reticulum membrane (MAM). It helps to locate endoplasmic reticulum calcium channels, regulates calcium homeostasis, and acts as a molecular chaperone to control cell fate and participate in signal transduction. It plays an important role in protecting neurons through a variety of signaling pathways and participates in the regulation of cognition and motor behavior closely related to neurodegenerative diseases. Based on its neuroprotective effects, Sig-1R has now become a breakthrough target for alleviating Alzheimer's disease and other neurodegenerative diseases. This article reviews the most cutting-edge research on the function of Sig-1R under normal or pathologic conditions and target drugs of the sigma-1 receptor in neurodegenerative diseases.

引用

页码：5649 / 5666

页数：18

共 50 条

[21] Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders
Maurice, Tangui
EXPERT OPINION ON DRUG DISCOVERY, 2021, 16 (04) : 373 - 389
[22] Sigma-1 receptor and seizures
Vavers, Edijs
Zvejniece, Liga
Dambrova, Maija
PHARMACOLOGICAL RESEARCH, 2023, 191
[23] The Sigma-1 Receptor in Cellular Stress Signaling
Hayashi, Teruo
FRONTIERS IN NEUROSCIENCE, 2019, 13
[24] Sigma-1 receptor:a potential new target for Parkinson's disease?
Veronica Francardo
Neural Regeneration Research, 2014, (21) : 1882 - 1883
[25] The activity of selective sigma-1 receptor ligands,in seizure models in vivo
Vavers, Edijs
Svalbe, Baiba
Lauberte, Lasma
Stonans, Ilmars
Misane, Ilga
Dambrova, Maija
Zvejniece, Liga
BEHAVIOURAL BRAIN RESEARCH, 2017, 328 : 13 - 18
[26] Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor
Hashimoto, Kenji
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2021, 271 (02) : 249 - 258
[27] Sigma-1 receptor: A drug target for the modulation of neuroimmune and neuroglial interactions during chronic pain
Carmen Ruiz-Cantero, M.
Gonzalez-Cano, Rafael
Tejada, Miguel A.
Santos-Caballero, Miriam
Perazzoli, Gloria
Nieto, Francisco R.
Cobos, Enrique J.
PHARMACOLOGICAL RESEARCH, 2021, 163
[28] Sigma-1 Receptor in Motoneuron Disease
Mancuso, Renzo
Navarro, Xavier
SIGMA RECEPTORS: THEIR ROLE IN DISEASE AND AS THERAPEUTIC TARGETS, 2017, 964 : 235 - 254
[29] Investigational sigma-1 receptor antagonists for the treatment of pain
Vela, Jose Miguel
Merlos, Manuel
Almansa, Carmen
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2015, 24 (07) : 883 - 896
[30] The emerging role of the sigma-1 receptor in autophagy: hand-in-hand targets for the treatment of Alzheimer's
Prasanth, Mani Iyer
Malar, Dicson Sheeja
Tencomnao, Tewin
Brimson, James Michael
EXPERT OPINION ON THERAPEUTIC TARGETS, 2021, 25 (05) : 401 - 414

← 1 2 3 4 5 →